CKD or death: death by 52 weeks · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in CKD or death: death by 52 weeks compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
CKD or death: 50% decline in GFR by 78 weeks · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in CKD or death: 50% decline in GFR by 78 weeks compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
Adverse effects (weeks 0 to 26): serious infection requiring hospitalisation · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in adverse events (weeks 0 to 26): serious infection requiring… compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
Adverse events: hypertension · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in adverse events (weeks 0 to 26): hypertension compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
Time‐scored functional assessments of muscle performance · people with facioscapulohumeral muscular dystrophy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with facioscapulohumeral muscular dystrophy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain · people with facioscapulohumeral muscular dystrophy
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Fatigue · people with facioscapulohumeral muscular dystrophy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with facioscapulohumeral muscular dystrophy
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Muscle strength: maximum voluntary isometric knee extension strength · people with facioscapulohumeral muscular dystrophy
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Aerobic capacity · people with facioscapulohumeral muscular dystrophy
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Time‐scored functional assessments of muscle performance: distance walked · people with facioscapulohumeral muscular dystrophy
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Quality of life · people with facioscapulohumeral muscular dystrophy
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Adverse event ‐ pain, visual analogue scale · people with facioscapulohumeral muscular dystrophy
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Fatigue · people with facioscapulohumeral muscular dystrophy
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Withdrawals due to adverse events · people with facioscapulohumeral muscular dystrophy
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Muscle strength · people with facioscapulohumeral muscular dystrophy
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Aerobic capacity · people with facioscapulohumeral muscular dystrophy
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Time‐scored functional assessments of muscle performance: distance walked · people with facioscapulohumeral muscular dystrophy
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Quality of life · people with facioscapulohumeral muscular dystrophy
1 finding from 1 review
no estimate extracted
Studies not reported
Very low